Dr Richard Franklin has over 40 years of experience in pharmaceutical research and development. He has worked in senior roles with Glaxo, Wyeth, Sterling Winthrop & Shire Pharmaceuticals where he was research fellow & head of new product innovation (small molecules). Dr Franklin is credited with filing over 40 patents on potential new drug products, published over 60 scientific papers, and was associate editor of the journal Xenobiotica for 10 years. He was also chair and secretary of the European Drug Metabolism Discussion Group. UK-based Dr Franklin was very much involved in the development and EU registration of anagrelide as Xagrid®
for the treatment of the orphan drug condition, Essential Thrombocythemia. His drug development experience covers a wide range of different products and therapeutic areas.
Richard Franklin
Follow
Get notifications in MyBN when activity occurs.
Richard Franklin
Project Director, Anagrelide / Arovella Therapeutics
Lists and Charts
Knowledge Bank : Person Roles
Year started and most recent title
Total Shareholder Return as at 05/02/26
| Rank | Company | 1 Yr | 5 Yr |
|---|---|---|---|
| 1561st | Kuniko | -54.57% | 0% |
| 1562nd | Coventry Group | -54.59% | -12.38% |
| 1563rd | Arovella Therapeutics | -54.74% | 14.87% |
| 1564th | HMC Capital Limited | -54.86% | 3.15% |
| 1565th | Australian Dairy Nutritionals Group | -55.16% | -13.11% |
1663 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
News Articles
Related Information
Access to our data for Richard Franklin is only available to paid subscribers with Data & Insights access.
Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.
Richard Franklin is linked to 1 organisation which is included in 1 list - Public Companies - non WA.
To see the data you will need to Subscribe.
X
